Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 254

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Azathioprine for Ocular Inflammatory Diseases

Open access
Pasadhika, Sirichai, Kempen, John H., Newcomb, Craig W., Liesegang, Teresa L., Pujari, Siddharth S., Rosenbaum, James T., Thorne, Jennifer E., Foster, C. Stephen, Jabs, Douglas A., Levy-Clarke, Grace A., Nussenblatt, Robert B., Suhler, Eric B.·2009·American Journal of Ophthalmology

Abstract

PURPOSE To evaluate treatment outcomes of azathioprine for noninfectious ocular inflammatory diseases. DESIGN Retrospective cohort study. METHODS Medical records of 145 patients starting azathioprine as a sole noncorticosteroid immunosuppressant at 4 tertiary uveitis services were reviewed. Main outcome measures included control of ocular inflammation, sustained control after tapering prednisone to </= 10 mg/day, and discontinuation of treatment because of side effects. RESULTS Among 145 patients (255 eyes) treated with azathioprine, 63% had uveitis, 23% had mucous membrane pemphigoid, 11% had scleritis, and 3% had other inflammatory diseases. By Kaplan-Meier analysis, 62% (95% confidence interval [CI], 50% to 74%) of patients with active disease initially gained complete inactivity of inflammation sustained over at least 28 days within 1 year of therapy, and 47% (95% CI, 37% to 58%) tapered systemic corticosteroids to </= 10 mg daily while maintaining control of inflammation within 1 year of therapy. Treatment success was most common for intermediate uveitis (90% with sustained inactivity within 1 year; 95% CI, 64% to 99%). Over the median follow-up of 230 days (interquartile range, 62 to 679 days), azathioprine was discontinued at a rate of 0.45 per person-years (/PY): 0.16/PY because of side effects, 0.10/PY because of ineffectiveness, 0.09/PY because of disease remission, and 0.10/PY because of unspecified causes. CONCLUSIONS Azathioprine was moderately effective as a single corticosteroid-sparing immunosuppressive agent in terms of control of inflammation and corticosteroid-sparing benefits, but required several months to achieve treatment goals; it seems especially useful for patients with intermediate uveitis. Treatment-limiting side effects occurred in approximately one-fourth of patients within 1 year, but typically were reversible.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajo.2009.05.008

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 254

Metadata

Authors
Pasadhika, S., Kempen, J. H., Newcomb, C. W., Liesegang, T. L., Pujari, S. S., Rosenbaum, J. T., Thorne, J. E., Foster, C. S., Jabs, D. A., Levy-Clarke, G. A., Nussenblatt, R. B., & Suhler, E. B.
Venue
American Journal of Ophthalmology
Publisher
Elsevier BV
Published
2009-10
Volume
148
Issue
4
Pages
500-509.e2
ISSN
0002-9394 (ISSN-L)
OpenAlex
W1974162532
Cited by
254
References
1
FWCI
10.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Azathioprine for Ocular Inflammatory Diseases. https://app.cochat.ai/papers/10.1016/j.ajo.2009.05.008
The paper
Pasadhika, S., Kempen, J. H., Newcomb, C. W., Liesegang, T. L., Pujari, S. S., Rosenbaum, J. T., Thorne, J. E., Foster, C. S., Jabs, D. A., Levy-Clarke, G. A., Nussenblatt, R. B., & Suhler, E. B. (2009). Azathioprine for Ocular Inflammatory Diseases. American Journal of Ophthalmology. https://doi.org/10.1016/j.ajo.2009.05.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.